<DOC>
	<DOCNO>NCT00074009</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes necessary growth . PURPOSE : Phase II trial study effectiveness bortezomib treat patient unresectable metastatic gastric cancer gastroesophageal junction adenocarcinoma .</brief_summary>
	<brief_title>Bortezomib Treating Patients With Unresectable Metastatic Gastric Cancer Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy bortezomib patient unresectable metastatic gastric gastroesophageal junction adenocarcinoma . Secondary - Determine toxicity drug patient . - Determine possible predictor response drug , use pretreatment tumor immunohistochemistry , patient . OUTLINE : This open-label , nonrandomized , multicenter study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 15-33 patient accrue study within 5-12 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable metastatic gastric gastroesophageal junction adenocarcinoma Siewert 's class II III disease Measurable disease At least 1 unidimensionally measurable lesion least 20 mm conventional technique OR least 10 mm spiral CT scan No history know active brain metastasis primary brain tumor PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % OR ECOG 02 Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 mg/dL AST ALT great 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal Creatinine great 1.5 mg/dL Cardiovascular No prior cerebrovascular event No prior orthostatic hypotension No myocardial infarction within past 6 month No peripheral vascular disease require surgical management No evidence acute ischemia significant conduction abnormality EKG Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 2 month study participation No evidence peripheral neuropathy No prior allergic reaction attribute compound similar chemical biological composition bortezomib No malignancy within past 3 year except basal cell skin cancer , carcinoma situ cervix , adequately treat nonmetastatic prostate cancer No ongoing active infection No psychiatric illness social situation would preclude study participation No concurrent uncontrolled illness would preclude study participation No medical condition reason would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy More 3 week since prior immunotherapy No concurrent biological immunological agent Chemotherapy No 1 prior chemotherapy regimen ( include adjuvant chemotherapy ) More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy More 3 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other Recovered prior therapy No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>